Samantha Perakis
Overview
Explore the profile of Samantha Perakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, et al.
Nat Commun
. 2020 Apr;
11(1):1965.
PMID: 32313081
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
2.
Smith C, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger A, et al.
Genome Med
. 2020 Mar;
12(1):23.
PMID: 32111235
Background: Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods: Here, a combination of untargeted and targeted...
3.
Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, et al.
Nat Commun
. 2019 Oct;
10(1):4666.
PMID: 31604930
Deregulation of transcription factors (TFs) is an important driver of tumorigenesis, but non-invasive assays for assessing transcription factor activity are lacking. Here we develop and validate a minimally invasive method...
4.
Heitzer E, Perakis S, Geigl J, Speicher M
NPJ Precis Oncol
. 2018 Jun;
1(1):36.
PMID: 29872715
Precision medicine refers to the choosing of targeted therapies based on genetic data. Due to the increasing availability of data from large-scale tumor genome sequencing projects, genome-driven oncology may have...
5.
Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, et al.
Int J Cancer
. 2018 Mar;
143(5):1236-1248.
PMID: 29574703
In patients with metastatic castrate-resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non-invasive biomarkers informative of treatment response with novel agents targeting...
6.
Moser T, Ulz P, Zhou Q, Perakis S, Geigl J, Speicher M, et al.
Clin Chem
. 2017 Aug;
63(10):1656-1659.
PMID: 28807979
No abstract available.
7.
Perakis S, Auer M, Belic J, Heitzer E
Adv Clin Chem
. 2017 Apr;
80:73-153.
PMID: 28431643
The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might revolutionize cancer care with respect to early detection, identification of minimal residual disease, assessment of...
8.
Perakis S, Speicher M
BMC Med
. 2017 Apr;
15(1):75.
PMID: 28381299
Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating...
9.
Seles M, Hutterer G, Kiesslich T, Pummer K, Berindan-Neagoe I, Perakis S, et al.
Int J Mol Sci
. 2016 Apr;
17(4):573.
PMID: 27092491
Renal cell carcinoma (RCC) represents a deadly disease with rising mortality despite intensive therapeutic efforts. It comprises several subtypes in terms of distinct histopathological features and different clinical presentations. Long...
10.
Ress A, Perakis S, Pichler M
Adv Exp Med Biol
. 2015 Dec;
889:89-103.
PMID: 26658998
Colorectal cancer (CRC) is one of the most common types of human cancer with high cancer-related morbidity and mortality rates. The development and clinical validation of novel therapeutic avenues have...